A Randomised, Double-blind Placebo-controlled Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of MIV-711 in Knee Joint Osteoarthritis

Trial Profile

A Randomised, Double-blind Placebo-controlled Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of MIV-711 in Knee Joint Osteoarthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs MIV 711 (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Medivir AB
  • Most Recent Events

    • 09 Nov 2017 Results presented in a Medivir AB media release.
    • 09 Nov 2017 Results presented at the 2017 annual meeting of the American College for Rheumatology (ACR), according to a Medivir AB media release.
    • 08 Nov 2017 Results assessing the safety and efficacy of MIV-711 in knee osteoarthritis patients, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top